Article Text

Download PDFPDF
CASE REPORT
High-dose steroids as a therapeutic option in the management of spur cell haemolytic anaemia
  1. Dhauna Karam1,
  2. Sean Swiatkowski2,
  3. Pant Purohit3,
  4. Bharat Agrawal3
  1. 1Department of Internal Medicine and Hemato-Oncology, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA
  2. 2Captain James A. Lovell Federal Health Care Center, North Chicago, Illinois, USA
  3. 3Medical Oncology/Medicine, Captain James A. Lovell Federal Health Care Center, North Chicago, Illinois, USA
  1. Correspondence to Dr Dhauna Karam, dhauna.karam{at}gmail.com

Summary

Spur cell haemolytic anaemia (SCA) is a form of anaemia that can be seen in patients with severely impaired liver function or advanced cirrhosis. It is associated with high mortality. The treatment options for SCA secondary to cirrhosis are limited. Our patient is a middle-aged man who developed SCA and was not a candidate for liver transplantation or splenectomy. High-dose steroids helped ameliorate haemolysis and improve anaemia and general condition of our patient.

  • cirrhosis
  • non-alcoholic steatosis
  • haematology (drugs and medicines)
  • medical management
  • therapeutic indications

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors DK was involved in the care of the patient and eventually wrote the initial manuscript. SS was the pathologist involved in the case and helped obtain images for the case report. PP helped collect references and reviewed the discussion part. BA was involved in the final correction and review of the manuscript. All authors have reviewed the final version of the manuscript and agreed with its conclusions.

  • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.